Related references
Note: Only part of the references are listed.Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
A. Gronchi et al.
ANNALS OF ONCOLOGY (2012)
Subtyping soft tissue sarcomas for treatment approaches
I. Judson et al.
ANNALS OF ONCOLOGY (2012)
New agents for the treatment of lymphoma
A. Stathis et al.
ANNALS OF ONCOLOGY (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
Xavier Garcia-del-Muro et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
Wells A. Messersmith et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Jean-Yves Blay et al.
CLINICAL CANCER RESEARCH (2008)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
Robert G. Maki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
R Garcia-Carbonero et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
